Single User License
INR 168725
Site License
INR 337450
Corporate User License
INR 506175

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Malignant Mesothelioma Global Clinical Trials Review, H2

Malignant Mesothelioma Global Clinical Trials Review, H2


  Request for Sample Report

Executive Summary

Malignant Mesothelioma Global Clinical Trials Review, H2, 2015

GlobalData's clinical trial report, "Malignant Mesothelioma Global Clinical Trials Review, H2, 2015" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Malignant Mesothelioma 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Unaccomplished Trials of Malignant Mesothelioma 25

Subjects Recruited Over a Period of Time 29

Clinical Trials by Sponsor Type 30

Prominent Sponsors 31

Top Companies Participating in Malignant Mesothelioma Therapeutics Clinical Trials 32

Prominent Drugs 33

Latest Clinical Trials News on Malignant Mesothelioma 34

Jun 15, 2015: EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients 34

Jun 01, 2015: Oral presentation at ASCO 2015 of survival data in poor prognosis patients achieved in the Phase III trial on NGR-hTNF treatment in pleural mesothelioma 34

May 30, 2015: Collaborative group phase III study shows Roche's Avastin improves survival in patients with mesothelioma-a devastating type of thoracic cancer 35

May 29, 2015: ArQule Announces Data Presentations with Tivantinib to Be Featured at ASCO 2015 36

May 27, 2015: Genelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma 36

May 07, 2015: Concordia Healthcare Works To Expand Treatment Options For Patients With Rare Cancers 38

Apr 17, 2015: Bionomics Showcases BNC105 Oncology Drug Development Program At 2015 AACR Annual Meeting 39

Clinical Trial Profiles 40

Clinical Trial Overview of Top Companies 40

Eli Lilly and Company 40

Clinical Trial Overview of Eli Lilly and Company 40

Novartis AG 42

Clinical Trial Overview of Novartis AG 42

AstraZeneca Plc 43

Clinical Trial Overview of AstraZeneca Plc 43

Verastem, Inc. 44

Clinical Trial Overview of Verastem, Inc. 44

Pfizer Inc. 45

Clinical Trial Overview of Pfizer Inc. 45

Merck Sharp & Dohme Corp. (Inactive) 46

Clinical Trial Overview of Merck Sharp & Dohme Corp. (Inactive) 46

Merck & Co., Inc. 47

Clinical Trial Overview of Merck & Co., Inc. 47

F. Hoffmann-La Roche Ltd. 48

Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 48

Eisai Inc. 49

Clinical Trial Overview of Eisai Inc. 49

Aduro BioTech, Inc. 50

Clinical Trial Overview of Aduro BioTech, Inc. 50

Clinical Trial Overview of Top Institutes / Government 51

National Cancer Institute 51

Clinical Trial Overview of National Cancer Institute 51

European Organization for Research and Treatment of Cancer 56

Clinical Trial Overview of European Organization for Research and Treatment of Cancer 56

Dana-Farber Cancer Institute, Inc. 57

Clinical Trial Overview of Dana-Farber Cancer Institute, Inc. 57

Memorial Sloan Kettering Cancer Center 58

Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 58

Hyogo College Of Medicine 59

Clinical Trial Overview of Hyogo College Of Medicine 59

Istituto Clinico Humanitas 60

Clinical Trial Overview of Istituto Clinico Humanitas 60

Sir Charles Gairdner Hospital 61

Clinical Trial Overview of Sir Charles Gairdner Hospital 61

The Cancer and Leukemia Group B 62

Clinical Trial Overview of The Cancer and Leukemia Group B 62

Abramson Cancer Center 63

Clinical Trial Overview of Abramson Cancer Center 63

Columbia University 64

Clinical Trial Overview of Columbia University 64

Five Key Clinical Profiles 65

Appendix 95

Abbreviations 95

Definitions 95

Research Methodology 96

Secondary Research 96

About GlobalData 97

Contact Us 97

Disclaimer 97

Source 98

List of Figures

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7

Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10

Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13

Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14

Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15

Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18

Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21

Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23

Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29

Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

GlobalData Methodology 96

List of Tables

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2015* 7

Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10

Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15

Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18

Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2015* 21

Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23

Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24

Malignant Mesothelioma Therapeutics, Global, Suspended Clinical Trials, 2015* 25

Malignant Mesothelioma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26

Malignant Mesothelioma Therapeutics, Global, Terminated Clinical Trials, 2015* 27

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29

Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32

Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015* 40

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 42

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 43

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Verastem, Inc., 2015* 44

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 45

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck Sharp & Dohme Corp. (Inactive), 2015* 46

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2015* 47

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 48

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Inc., 2015* 49

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Aduro BioTech, Inc., 2015* 50

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 51

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2015* 56

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, Inc., 2015* 57

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 58

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Hyogo College Of Medicine, 2015* 59

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Istituto Clinico Humanitas, 2015* 60

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sir Charles Gairdner Hospital, 2015* 61

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cancer and Leukemia Group B, 2015* 62

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Abramson Cancer Center, 2015* 63

Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2015* 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Eli Lilly and Company

Novartis AG

AstraZeneca Plc

Verastem, Inc.

Pfizer Inc.

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

Eisai Inc.

Aduro BioTech, Inc.

Malignant Mesothelioma Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Malignant Mesothelioma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com